University of Texas Health Science Center at San Antonio-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2023

  1. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 59, Núm. 2, pp. 90-100

2022

  1. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  2. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

2021

  1. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

    Chest, Vol. 159, Núm. 1, pp. 58-72

2020

  1. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (BMC Infectious Diseases, (2018), 18, 1, (677), 10.1186/s12879-018-3565-z)

    BMC Infectious Diseases

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

  2. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

    Journal of Infection, Vol. 79, Núm. 4, pp. 300-311

  3. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients

    Clinical Infectious Diseases, Vol. 68, Núm. 9, pp. 1482-1493

2018

  1. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients

    European Respiratory Journal, Vol. 52, Núm. 2

  2. Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study

    ERJ Open Research, Vol. 4, Núm. 4

2017

  1. Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: A cohort study

    BMC Geriatrics, Vol. 17, Núm. 1

2016

  1. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

    The Lancet Infectious Diseases, Vol. 16, Núm. 12, pp. 1364-1376

2015

  1. Anti-C1q antibodies in systemic lupus erythematosus

    Lupus, Vol. 24, Núm. 1, pp. 42-49

  2. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  3. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

2012

  1. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2677-2686

2011

  1. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies

    Lupus

2010

  1. Effect of nateglinide on the incidence of diabetes and cardiovascular events

    New England Journal of Medicine, Vol. 362, Núm. 16, pp. 1463-1476

  2. Effect of valsartan on the incidence of diabetes and cardiovascular events

    New England Journal of Medicine, Vol. 362, Núm. 16, pp. 1477-1490

2005

  1. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico

    Journal of Clinical Microbiology, Vol. 43, Núm. 8, pp. 4159-4162